Urinary oxalate excretion in urolithiasis and nephrocalcinosis

Thomas J Neuhaus, Tanja Belzer, Nenad Blau, Bernd Hoppe, Harmeet Sidhu, Ernst Leumann

Abstract

Aims—To investigate urinary oxalate excretion in children with urolithiasis and/or nephrocalcinosis and to classify hyperoxaluria (HyOx).

Methods—A total of 106 patients were screened. In those in whom the oxalate:creatinine ratio was increased, 24 hour urinary oxalate excretion was measured. Liver biopsy and/or genomic analysis was performed if primary hyperoxaluria (PH) was suspected. Stool specimens were examined for Oxalobacter formigenes in HyOx not related to PH type 1 or 2 (PH1, PH2) and in controls.

Results—A total of 21 patients screened had HyOx (>0.5 mmol/24 h per 1.73 m²); they were classified into five groups. Eleven had PH (PH1 in nine and neither PH1 nor PH2 in two). Six had secondary HyOx: two enteric and four dietary. Four could not be classified. Seven patients had concomitant hypercalciuria. Only one of 12 patients was colonised with O formigenes compared to six of 13 controls.

Conclusions—HyOx is an important risk factor for urolithiasis and nephrocalcinosis in children, and can coexist with hypercalciuria. A novel type of PH is proposed. Absence of O formigenes may contribute to HyOx not related to PH1.

(Keywords: hyperoxaluria; nephrocalcinosis; urolithiasis; Oxalobacter formigenes)

The current prevalence of paediatric urolithiasis in Europe is low with an estimated rate of 1–5 in 10 000 children. However, it is the cause of considerable morbidity and has a high risk of recurrence. Diagnosis is often delayed in infants and young children as they may present with non-specific symptoms, for example, abdominal pain, microhaematuria, or presumed urinary tract infection. Occasionally, urolithiasis or nephrocalcinosis are detected incidentally on ultrasound or abdominal x ray.

The majority of renal calculi in children are (as in adults) composed of calcium oxalate. Calcium oxalate stones are commonly attributed to (idiopathic) hypercalciuria although the aetiology often remains undetermined. Only a few children suffer from inherited disorders, for example, primary hyperoxaluria type 1 or type 2 (PH1, PH2). Renal tubular acidosis, or Dent’s disease. Metabolic screening of paediatric renal stone formers is essential, but is often confined to urinary calcium, cystin, and uric acid excretion, although hyperoxaluria (HyOx) and hypocitraturia contribute to the formation of calcium oxalate stones.

Persistent HyOx in children is often related to PH1 or PH2. Enteric HyOx is the consequence of malabsorption and steatorrhea, for example, in patients with short bowel syndrome, inflammatory bowel disease, and cystic fibrosis. Excessive intake of nutrients high in oxalate content (for example, beetroot, dark chocolate, ice tea, rhubarb, spinach) may result in transient dietary HyOx. Recently, the absence of intestinal Oxalobacter formigenes, an oxalate degrading bacterium, has been reported as a potential risk factor for HyOx in children with cystic fibrosis.

The objectives of this study were: (1) the investigation of the urinary oxalate excretion in children with urolithiasis and/or nephrocalcinosis; and (2) classification and follow up of the patients with HyOx.

Patients and methods

PATIENTS

All 106 patients with a diagnosis of urolithiasis and/or nephrocalcinosis seen between 1990 and 1997 were enrolled in the study; 75 children (49 boys) had urolithiasis, 20 (seven boys) had nephrocalcinosis, and 11 (eight boys) had both urolithiasis and nephrocalcinosis. Age at presentation ranged from 2 weeks to 14 years. In addition, all siblings of patients with PH were investigated. Patients with known secondary forms of nephrocalcinosis (ex-prematures who had received furosemide, patients with hypophosphataemic rickets or vitamin D intoxication) were excluded. Our hospital is both a primary care centre for the greater area of Zurich and a tertiary referral centre for the eastern part of Switzerland. Children with urolithiasis and nephrocalcinosis are referred if they have metabolic disturbances (for example, hypercalciuria), require extracorporeal shock wave lithotripsy, or have renal insufficiency.

METHODS

Screening was performed by determination of the oxalate:creatinine ratio in an acidified spot morning urine. If the ratio was increased compared with sex and age related normal values, at least one 24 hour urinary collection was performed to measure oxalate, glycolate, glycerate, and calcium excretion. The urine was directly voided into sampling bottles, containing 10 ml 6 M HCl per litre of urine. An aliquot was stored at −20°C and
analysed within one month. The adequacy of urine collection was checked by comparing the measured creatinine excretions with normal values. A dietary history was taken with emphasis on calcium and oxalate intake. The extent of nephrocalcinosis was graded according to the sonographic findings (grades 1–3). 

Urinary concentrations of citrate, magnesium, phosphate, potassium, sodium, sulphate, and uric acid, and urinary pH were also measured. Urinary calcium oxalate saturation was calculated from these parameters using a PC based computer program (EQUIL 2). Results were compared with sex and age related values. Separation and quantification of oxalate, citrate, glycerate, glycolate, and sulphate was performed using a Dionex Series 4000i gradient ion chromatography system (Dionex, Sunnyvale, California). Low background conductivity was ensured by addition of 25 mM sulphuric acid. Other solutes were measured with a Synchron CX-6 analyser (Beckmann, Brea, California): calcium (colorimetric cresolphthalein complex method), creatinine (standard kinetic Jaffe procedure), magnesium (xylidyl blue reaction), phosphate (ultraviolet molybdat method), potassium and sodium (ion selective electrodes). As urinary collections were acidified, uric acid (uricase method) and urinary pH were measured in a fresh morning urine following the collection. Renal stones were analysed by x ray diffraction. Normal 24 hour urinary excretion values for oxalate, glycolate, citrate, and calcium were defined as: oxalate <0.5 mmol, glycolate <0.5 mmol, and citrate >0.8 mmol per 1.73 m² body surface area; calcium ≤0.1 mmol per kg body weight.

Liver biopsy and/or molecular analysis were performed in patients with suspected PH (G Rumsby, University College London Hospitals, London, UK). The catalytic activity and the level of immunoreactive alanine:glyoxylate aminotransferase (AGT) protein (PH1), and the catalytic activity of glyoxylate reductase/hydroxypyruvate reductase (PH2) were included by liver biopsy which showed normal background levels. Stones of both patients were composed of calcium oxalate (70% monohydrate, 30% dihydrate). There was no evidence of malabsorption, and dietary oxalate intake was normal. PH1 and PH2 were definitely excluded by liver biopsy which showed normal catalytic activity and immunoreactivity of alanine:glyoxylate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Treatment included high fluid intake, dietary oxalate restriction, and administration of potassium citrate and calcium, and citrate excretion were normal. Stones of both patients were composed of calcium oxalate (70% monohydrate, 30% dihydrate). There was no evidence of malabsorption, and dietary oxalate intake was normal. PH1 and PH2 were definitely excluded by liver biopsy which showed normal catalytic activity and immunoreactivity of alanine:glyoxylate aminotransferase and glyoxylate reductase/hydroxypyruvate reductase. Treatment included high fluid intake, dietary oxalate restriction, and administration of potassium citrate and pyridoxine. Although therapy had no effect on urinary oxalate excretion, both patients have not formed further stones so far. Both have a slightly increased plasma creatinine concentration.

SECONDARY HYPEROXALURIA

Enteric hyperoxaluria

Two patients with recurrent calcium oxalate stones (60% monohydrate, 40% dihydrate) suffered from enteric HyOx after extensive jejunoileal resection (table 1; patients 3 and 4). HyOx was inconsistent and ranged from <0.5 to >1.0 mmol/24 h per 1.73 m². Urinary calcium excretion fluctuated from normal to high. Urinary citrate (off treatment) was persistently low in both patients (0.25–0.7 mmol/24 h per 1.73 m², patient 3; 0.07–0.5, patient 4). High fluid intake, dietary oxalate restriction, and potassium citrate were given. High fluid intake was difficult to achieve in one patient (patient 3) as it caused diarrhoea; her plasma creatinine was slightly increased. The normocalciuric patient (patient 4) received oral calcium supplementation.
Non-classified hyperoxaluria

No plausible explanation was found for the intermittent HyOx in four patients (table 1; patients 5–7) and one (patient 8)—as advised elsewhere—had vigorous calcium restriction. Family history was positive for urolithiasis in two patients (patients 6 and 7). Urinary citrate excretion was always normal. All examined stones were composed of a mixture of calcium oxalate monohydrate and dihydrate. After adjusting the dietary habits, urinary oxalate excretion returned to normal, haematuria disappeared, and the further clinical course was uneventful in all four patients.

Dietary hyperoxaluria

Dietary diaries and notable fluctuation of HyOx suggested dietary HyOx in four children. Three had an excessive oxalate intake (table 1; patients 5–7) and one (patient 8)—as advised elsewhere—had vigorous calcium restriction. Family history was possible for urolithiasis in two patients (patients 6 and 7). Urinary citrate excretion was always normal. All examined stones were composed of a mixture of calcium oxalate monohydrate and dihydrate. After adjusting the dietary habits, urinary oxalate excretion returned to normal, haematuria disappeared, and the further clinical course was uneventful in all four patients.

Oxalobacter formigenes

Stool specimens were examined for O formigenes in all 12 patients with HyOx not related to PH1. Only one (patient 9; 8%) was colonised compared to six of 13 (46%) controls. All controls had urinary oxalate:creatinine ratio in the normal range; the ratio was slightly, but not significantly lower in the colonised group compared to the non-colonised group (32 versus 46 mmol/mol).

None of the 21 patients had hyperuricosuria.4 Urinary sodium excretion was not significantly different between the seven hypercalciuric patients compared to the 14 normocalciuric patients (71 versus 83 mmol/24 h per m²).

Discussion

The majority of renal stones in children are composed of calcium oxalate.1–4 Several factors contribute to the formation of calcium oxalate crystals: HyOx, hypercalcemia, hypocitraturia, low urinary volume, anatomical malformations with urinary stasis, and dietary habits.1–4 7–11 Our data confirm the importance of HyOx as a risk factor for urolithiasis and/or nephrocalcinosis in children. HyOx was present in a substantial percentage of patients with either urolithiasis or nephrocalcinosis. Moreover, HyOx was found in almost all children presenting with both urolithiasis and nephrocalcinosis.

Routine urinary oxalate determination is not common practice as collection and measurement of urinary oxalate are laborious and delicate. Indeed, a recent nationwide US survey on diagnostic procedures showed that even in patients with suspected PH urinary oxalate was only measured in 61.5% of these patients.16 Urinary oxalate excretion has only rarely been investigated in paediatric stone formers. Two studies, one from Germany28 and one from India,29 have shown a similar prevalence of HyOx—15% (six of 40 patients) and 9% (three of 32), respectively. Classification of HyOx may be difficult. HyOx was associated with primary hyperoxaluria in less than half of our patients. Children with PH1 or PH2 usually have notable and

### Table 1 Clinical and laboratory findings of 12 patients with hyperoxaluria (not related to PH1 or PH2)

<table>
<thead>
<tr>
<th>Patient no.</th>
<th>Urolithiasis*</th>
<th>Nephrocalcinosis†</th>
<th>24 h urinary collections (n)</th>
<th>&lt;0.5</th>
<th>≥0.5</th>
<th>≥1.0</th>
<th>Elevated calcium oxalate saturation‡</th>
<th>Hypercalciuria (≥0.1 mmol/24 h per kg) (n)</th>
<th>Current age (n)</th>
<th>Plasma creatinine (µmol/l)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Primary hyperoxaluria, neither PH1 nor PH2</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>1 S Absent</td>
<td>7</td>
<td>0</td>
<td>1</td>
<td>6</td>
<td>4</td>
<td>0</td>
<td>1</td>
<td>4.8</td>
<td>64</td>
<td></td>
</tr>
<tr>
<td>2 S Absent</td>
<td>8</td>
<td>0</td>
<td>4</td>
<td>4</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>4.4</td>
<td>61</td>
<td></td>
</tr>
<tr>
<td>Secondary hyperoxaluria: enteric hyperoxaluria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>3 R Absent</td>
<td>7</td>
<td>4</td>
<td>3</td>
<td>0</td>
<td>3</td>
<td>5</td>
<td>5</td>
<td>11.9</td>
<td>81</td>
<td></td>
</tr>
<tr>
<td>4 R Absent</td>
<td>11</td>
<td>0</td>
<td>3</td>
<td>8</td>
<td>9</td>
<td>0</td>
<td>15.0</td>
<td>78</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Secondary hyperoxaluria: dietary hyperoxaluria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>5 S Absent</td>
<td>5</td>
<td>3</td>
<td>1</td>
<td>1</td>
<td>2</td>
<td>1</td>
<td>1</td>
<td>16.8</td>
<td>79</td>
<td></td>
</tr>
<tr>
<td>6 R 2</td>
<td>10</td>
<td>5</td>
<td>3</td>
<td>2</td>
<td>5</td>
<td>9</td>
<td>9</td>
<td>15.5</td>
<td>57</td>
<td></td>
</tr>
<tr>
<td>7 R Absent</td>
<td>8</td>
<td>5</td>
<td>3</td>
<td>0</td>
<td>4</td>
<td>2</td>
<td>2</td>
<td>20.8</td>
<td>70</td>
<td></td>
</tr>
<tr>
<td>8 S Absent</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>1</td>
<td>0</td>
<td>0</td>
<td>11.7</td>
<td>60</td>
<td></td>
</tr>
<tr>
<td>Non-classified hyperoxaluria</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>9 R 3</td>
<td>12</td>
<td>3</td>
<td>8</td>
<td>1</td>
<td>1</td>
<td>12</td>
<td>12</td>
<td>14.0</td>
<td>87</td>
<td></td>
</tr>
<tr>
<td>10 S Absent</td>
<td>11</td>
<td>6</td>
<td>5</td>
<td>0</td>
<td>7</td>
<td>9</td>
<td>9</td>
<td>10.3</td>
<td>73</td>
<td></td>
</tr>
<tr>
<td>11 – 2</td>
<td>12</td>
<td>5</td>
<td>6</td>
<td>1</td>
<td>11</td>
<td>9</td>
<td>11.8</td>
<td>63</td>
<td></td>
<td></td>
</tr>
<tr>
<td>12 S Absent</td>
<td>3</td>
<td>1</td>
<td>2</td>
<td>0</td>
<td>2</td>
<td>3</td>
<td>13.5</td>
<td>70</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

* S, single; R, recurrent episode(s) of urolithiasis. † See Patriquin and Robitaille.‡ See Hoppe et al.
persistent elevation of urinary oxalate excretion (>1 mmol/24 h per 1.73 m²) and normal or low urinary calcium excretion. Some rare patients also have hypercalciuria. Liver biopsy and/or molecular analysis confirm the clinical diagnosis, but do not predict the outcome.24 25 The clinical course of PH1 is variable between patients and within families.5 6 24 25 26 Family screening has shown completely asymptomatic siblings with PH1.24

Two patients with persistent HyOx had clinical and urinary findings compatible with primary hyperoxaluria, but both PH1 and PH2 were excluded by liver biopsy. In contrast to patients with PH1,19 the stones contained not only calcium oxalate monohydrate, but also calcium oxalate dihydrate. Oxalate restriction and long term administration of pyridoxine had no effect on HyOx. These findings suggest a novel type of primary hyperoxaluria, different from PH1 and PH2, tentatively called "atypical PH". Further evidence for a novel type was recently presented at the 5th Workshop on Primary Hyperoxaluria.30

Secondary hyperoxaluria is either enteric or dietary, apart from intoxication. Enteric HyOx resulting from malabsorption and steatorrhoea has only occasionally been reported in children.16 21 In patients with enteric HyOx, calcium binds to fatty acids instead of oxalate, and this soluble oxalate is better absorbed. Hypocitraturia—in this series to enteric HyOx—is an additional lithogenic risk factor in these patients, and is caused at least in part by intestinal alkali loss.25 Dietary HyOx results from excessive intake of nutrients high in oxalate content (or vigorous calcium restriction), and is usually associated with intermittent and variable HyOx depending on oxalate intake.5 21 However, only 5–10% of the urinary oxalate normally originates from daily nutrition, and this fraction is even lower in patients with PH1, considering their high endogenous oxalate production.5 25 Repeated 24 hour urinary collections and a dietary history are mandatory.

A few patients with intermittent HyOx and concomitant hypercalciuria could not be classified as there was no evidence of primary or secondary HyOx based on clinical and urinary findings. The combination of hypercalciuria and HyOx exerted a synergistic effect on the elevation of urinary calcium oxalate saturation with subsequent formation of urolithiasis and nephrocalcinosis.

The calculation of the urinary calcium oxalate saturation (EQUIL 2), incorporating various lithogenic and inhibitory substances, is a tool to assess the risk of stone formation.18 Although its predictive value is controversial in adult stone formers17 and could not strictly be proven in this study, the data on urinary calcium oxalate saturation were helpful for the clinical guidance of HyOx children. If urinary calcium oxalate saturation was increased, suggesting at least partial non-compliance, patients were warned and adjusted to adhere more strictly to treatment consisting of high fluid intake, citrate administration and—except in PH1—dietary oxalate restriction.25

If end stage renal failure occurs in PH, combined liver-kidney transplantation is required.22 In the past, many adult idiopathic calcium oxalate stone formers were advised to adopt a low calcium diet. However, this may lead to increased intestinal oxalate absorption and subsequent HyOx, as less calcium is available to bind oxalate and to form poorly absorbable calcium oxalate complexes in the gut.7 32 Indeed, even a minor increase of the urinary concentration of oxalate (but not of calcium) exerts a substantial lithogenic effect.7 33 Keeping in line with this concept is a recent study showing that high calcium intake prevents further stone formation.22

The absence of O. formigenes from the intestinal tract has recently been reported as a potential risk factor for HyOx in children with cystic fibrosis.13 O. formigenes scavenges and degrades dietary oxalate in the human gut and creates a transepithelial gradient favourable for secretion of oxalate. In PH1, intestinal absorption of endogenous oxalate is of little relevance compared to gross endogenous overproduction. On the other hand, absence of O. formigenes and subsequent increased intestinal oxalate absorption may contribute to the excessive urinary oxalate excretion in the other forms of HyOx, as oxalate production was assessed to one third of these formers as compared to up to 70% in healthy populations.23 However, more data on larger patient groups are needed.

CONCLUSIONS
(1) Hyperoxaluria is an important risk factor in children with urolithiasis and/or nephrocalcinosis, and can coexist with hypercalciuria. Thus, initial routine diagnostic work up requires measurement of urinary oxalate. (2) Classification of HyOx is difficult. (3) At least one novel type of PH besides PH1 and PH2 is proposed. (4) Absence of O. formigenes may contribute to HyOx.

We thank Mrs Ana Matasovíc for her technical work and Dr G Rumsby for performing the enzymic and molecular analysis.

MilliPaed 2000 Congress

17–21 May 2000, Sun City, South Africa

This biennial conference of the South African Paediatric Association and the South African Association of Paediatric Surgeons aims to meet the medical and surgical needs of children in South Africa but will be of interest to delegates worldwide. The scientific program will provide a blend of original research, and state of the art review for which this meeting is renowned. Plenary sessions include medical information technology, advances in neonatology, epilepsy: “should we be treating fits?”, management of short stature, and much more.

For further details of the congress, please contact: Mrs Yvonne Pyne-James, RSVP Events Management c.c., PO Box 1105, Cramerview 2060, South Africa (tel: +27 11 463 4064, fax: +27 11 463 1041, e-mail: rsvp@yebo.co.za, website: www.millipaed.co.za).